Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on the Suspension of the Consultation Procedure under Section 35a paragraph 3b SGB V: Lifileucel (melanoma); requirement of routine practice data collection and evaluations

of 16 October 2025

The Federal Joint Committee (G-BA) decided the following at its session on 16 October 2025:

I. The consultation procedure on the requirement of routine practice data collection and evaluations according to Section 35a paragraph 3b SGB V for the active ingredient lifileucel for the treatment of

"Adults with unresectable or metastatic melanoma who have been previously treated with a PD-1 blocking antibody and, if a BRAF V600 mutation is present, with a BRAF inhibitor with or without an MEK inhibitor."

is suspended.

II. The resolution will enter into force on the day of its publication on the website of the G-BA on 16 October 2025.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 16 October 2025

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken